We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
George Yaghmour
Oct 05, 2015
Interesting case, Clear cell papillary carcinoma if it is pure has low risk of recurrence. Mairo L. et al and colleagues discussed that pure CCPRCC is an indolent tumor and should be renamed “clear cell papillary neoplasm of low malignant potential” to reflect their biology. It was retrospective, and 21 months follow up. No strong evidence but would consider surveillance follow up .
In reference to Dr. Yagmour’s assessment of the case, he suggests that this could be the described entity of clear cell papillary renal carcinoma (CCPRC) referenced here with attached commentary. If that is the pathology that is being described here, the prognosis is really excellent as CCPRC is biologically a very indolent process that almost never metastasizes. Please see the Hopkin’s series in the attached article for more information. However, I will caution, in this case I question this as a diagnosis in that there was a 2.4cm paracaval LN with extracapsular extension describing a tumor which clearly is more biologically aggressive. I would thus have the pathology reviewed by a higher volume center. I suppose we would have to follow the biology here in that it clearly is behaving more aggressively and thus prognostically would be a greater risk. However, unfortunately all adjuvant therapy trials to date have failed to show any efficacy. Thus, if there is an adjuvant clinical trial available, I would consider that for this patient. The histology and biology are also important to understand in that I would also be more inclined to radiographically surveil him if more aggressive.
George Yaghmour
Nov 02, 2015
Thank you Dr. Somer for your inputs. Interesting point to consider the clinical course and risk feature by the behavior and consider surveillance or adjuvant clinical trial . Do you think adding biomarker genome alteration test would help further decision in treatment and follow up ?
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
George Yaghmour
Oct 05, 2015
Bradley G. Somer MD
Oct 26, 2015
George Yaghmour
Nov 02, 2015
Apr 19, 2024
Pending Moderator approval.